Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treating interdialytic hyperkalemia with fludrocortisone.

Louis J Imbriano, John H Durham, John K Maesaka

    Seminars in Dialysis
    |January 22, 2003
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Importance of Capillary Leak and Nocturia in Defining and Successfully Treating Idiopathic Edema.

    Journal of clinical medicine·2025
    Same author

    The Different Paths That Lead to Hypotonic Hyponatremia, and a Safe Approach to Treatment.

    Journal of clinical medicine·2025
    Same author

    Successful treatment of unusual life-threatening complications of idiopathic edema.

    The American journal of the medical sciences·2024
    Same author

    High prevalence of renal salt wasting induced by haptoglobin-related protein without signal peptide is linked to new syndrome of salt wasting in Alzheimer disease.

    Kidney research and clinical practice·2023
    Same author

    Haptoglobin-Related Protein without Signal Peptide as Biomarker of Renal Salt Wasting in Hyponatremia, Hyponatremia-Related Diseases and as New Syndrome in Alzheimer's Disease.

    Biomolecules·2023
    Same author

    Cerebral Salt Wasting Is a Real Cause of Hyponatremia: PRO.

    Kidney360·2023

    Hyperkalemia is a serious risk for dialysis patients. Fludrocortisone may help manage potassium levels by utilizing the colon

    Area of Science:

    • Nephrology and Internal Medicine
    • Endocrinology

    Background:

    • Hyperkalemia is a common and dangerous complication in patients undergoing dialysis.
    • Existing treatments for hyperkalemia face challenges due to intra- and extracellular potassium compartmentalization.

    Discussion:

    • The colon, in addition to the kidneys, plays a role in potassium excretion.
    • Aldosterone influences fecal potassium excretion, suggesting a potential therapeutic pathway.
    • Fludrocortisone, a mineralocorticoid agonist, is explored as a method to enhance colonic potassium secretion.

    Key Insights:

    • The colon's excretory capacity for potassium offers a therapeutic target for managing hyperkalemia.
    • Fludrocortisone may provide an alternative to potentially hazardous intradialytic interventions for lowering potassium.

    Related Experiment Videos

  • Understanding the interplay between mineralocorticoids and colonic potassium transport is crucial.

    • Outlook:

    • Further research into fludrocortisone's efficacy and safety in dialysis patients with hyperkalemia is warranted.
    • This approach could lead to improved management strategies for hyperkalemia, reducing the need for invasive procedures.